Fate Therapeutics (FATE) Stock Forecast & Price Target

$1.68 +0.02 (+1.20%)

(As of 12/20/2024 05:40 PM ET)

Fate Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 10 Analyst Ratings

Sell
0

Hold
7

Buy
3

Based on 10 Wall Street analysts who have issued ratings for Fate Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a buy rating for FATE.

Consensus Price Target

$6.75
301.79% Upside

According to the 10 analysts' twelve-month price targets for Fate Therapeutics, the average price target is $6.75. The highest price target for FATE is $10.00, while the lowest price target for FATE is $5.00. The average price target represents a forecasted upside of 301.79% from the current price of $1.68.

Get the Latest News and Ratings for FATE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fate Therapeutics and its competitors.

FATE Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	12 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$6.75	$6.75	$6.90	$6.57
Forecasted Upside	301.79% Upside	194.76% Upside	89.56% Upside	92.15% Upside
Consensus Rating	Hold	Hold	Hold	Hold

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

FATE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FATE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fate Therapeutics Stock vs. The Competition

Type	Fate Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.30	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	301.79% Upside	25,828.18% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent FATE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Hold
11/18/2024	Bank of America 3 of 5 stars		Upgrade	Underperform ➝ Neutral
11/12/2024	Wedbush 4 of 5 stars		Reiterated Rating	Neutral	$5.00	+110.08%
8/22/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$5.00 ➝ $5.00	+27.88%
6/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Tenthoff Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.00 ➝ $6.00	+66.20%
5/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$11.00 ➝ $9.00	+116.35%
Get the Latest News and Ratings for FATE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
5/10/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$7.00 ➝ $6.00	+44.23%
2/27/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $7.00	+0.72%
2/27/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$6.00 ➝ $10.00	+38.89%
2/27/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform
11/20/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$12.00 ➝ $8.00	+198.51%
11/9/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00	+104.92%
9/7/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$5.00	+102.43%
8/16/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$7.00	+146.48%
5/4/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$5.30 ➝ $5.00	-20.38%
3/2/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$9.00 ➝ $10.00	+64.20%
3/1/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$10.00	+58.23%
1/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$62.00 ➝ $10.00	-9.09%
1/3/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:20 AM ET.

FATE Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Fate Therapeutics is $6.75, with a high forecast of $10.00 and a low forecast of $5.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
: According to analysts, Fate Therapeutics's stock has a predicted upside of 301.79% based on their 12-month stock forecasts.
: Over the previous 90 days, Fate Therapeutics's stock had 1 upgrade by analysts.
: Fate Therapeutics has been rated by research analysts at Bank of America, Needham & Company LLC, and Wedbush in the past 90 days.
: Analysts like Fate Therapeutics less than other "medical" companies. The consensus rating for Fate Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FATE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

This page (NASDAQ:FATE) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Stock Forecast & Price Target